Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

To be part of this important study, you need to be at least 30 years old. You must have been diagnosed with Multiple System Atrophy (MSA), specifically the Parkinsonian (MSA-P) or cerebellar (MSA-C) type. Your diagnosis will be reviewed by a special committee to make sure the study is right for you. You also need to experience the dizzy spells associated with neurogenic orthostatic hypotension (nOH), which means your blood pressure drops significantly when you stand up.

There are also some things that might mean you can't join the study. For example, if you have other serious illnesses that could cause similar symptoms or interfere with the study medicine, you might not be eligible. If you're pregnant, breastfeeding, or planning to become pregnant, you won't be able to participate. Likewise, if you're a woman who could become pregnant or a man who could father a child, you'll need to agree to use effective birth control during and shortly after the study.

Finally, you need to be able to talk easily with the study doctors and nurses, understand what's involved in the study, and be willing to follow the study's instructions and attend appointments. Certain medications might also need to be avoided during the study.

If you decide to take part, the study will involve several stages. First, there's a 'screening' period where doctors will check if the study is right for you. This will include checks on your MSA diagnosis and how your blood pressure changes when you stand.

After screening, if you're eligible, you'll enter the 'open-label' period. This means everyone will receive the study medicine, Ampreloxetine, for a while. Then comes the 'randomized withdrawal' stage: some people will continue on Ampreloxetine, and others will switch to a 'placebo' or dummy pill. You won't know which one you're getting at this point. This part helps researchers compare the medicine to no medicine to see its effects properly. This main treatment period will last about 20 weeks.

Throughout the study, you'll have regular hospital or clinic visits. During these visits, doctors and nurses will monitor your health, check your blood pressure, ask about your nOH symptoms, and perform other tests. Some participants might also be offered a chance to continue taking Ampreloxetine in a 'long-term treatment extension' period after the main study, to see its effects over a longer time. You'll need to remember to take your medication as instructed and attend all scheduled appointments.